Slide 1: For personal use only
For personal"wse only 2300 NEWTON 7, dorsaVi
Slide 2: dorsaVi wearable technology overview
dorsaVi’s wearable technology measures quality of For personal use only movement in OHS, Clinical and Elite Sports environments. We provide objective, easy to interpret data that creates actionable results for workers, patients and athletes. • dorsaVi Ltd (ASX: DVL) listed in Dec 2013 • Multiple pat
Slide 3: Points of Differentiation
Points of Differentiation For personal use only • 6 patents using sensors and analysing human movement • Develop own hardware, firmware, software • Sensor system best in class in terms of accuracy • 2 to 8 sensors with automated analysis and reporting • FDA clearance for medical grade wearable • Fir
Slide 4: Financial Overview
Financial Overview For personal use only dorsaVi Ltd (ASX : DVL) Share price $0.35 Shares on issue 149,914,616 Market capitalisation $52.5 million * 2013 2014 2015 H1 2016* Revenue** 398,607 529,380 1,358,218 1,291,989* EBITDA (2,148,749) (3,852,593) (8,684,709) (3,292,932) Loss from continuing (1,6
Slide 5: Financial Overview – Comparison (H1 FY15 vs H1FY16)
Financial Overview – Comparison (H1 FY15 vs H1FY16) For personal use only • Increased scale and size of OHS clients Revenue 110% • • • Repeat OHS deals with major clients Recent launch of OHS in US & UK Increase in clinical trial sites via large US & UK deals • Large Chains coming on board Device Sa
Slide 6: Revenue Growth – Jurisdictional Comparison
Revenue Growth – Jurisdictional Comparison For personal use only
Slide 7: Highlights from H1
Highlights from H1 For personal use only ViSafe (OHS) • Launched OHS product into the UK and the US • New contracts with major OHS clients in UK & US (Toyota, Jaguar, TFL, Heathrow) • Repeat & large scale OHS deals contracts (TFL, Crown and Monash/Allianz) ViMove (Clinical) • Beachhead Clients • UK:
Slide 8: Providing the Movement Metrics needed for Decision Making in OHS
Providing the Movement Metrics needed for Decision Making in OHS For personal use only • Work injuries cost $250B p.a. (US) • Unique movement data determines high risk activities • Interventions involving: • Job assessment, Equip change, Pre employ screen • Better decisions based on fact, not opinio
Slide 9: Making a huge commercial difference to our clients
Making a huge commercial difference to our clients For personal use only • Case study from large organisation 72 injuries Q1 2014 • Used dorsaVi sensors to identify risk & plan changes • Third party – pre employment screening 1 injury Q1 2015 • Consumable revenue from 300+ screenings to dorsaVi by •
Slide 10: RISK CLAIMS
For personal use only RISK 10 CLAIMS
Slide 11: RISK CLAIMS
For personal use only RISK 11 CLAIMS
Slide 12: RISK CLAIMS Foundation Project
For personal use only RISK CLAIMS P Foundation Project feeds other commercial projects
Slide 13: Achieving the 'Triple Bottom Line' with large corporates
Achieving the ‘Triple Bottom Line’ with large corporates For personal use only 1. Reduce Costs & Injuries 2. Improve Safety Culture 3. Improve Productivity 13
Slide 14: Effective healthcare at lower cost
Effective healthcare at lower cost $560B For personal use only • Health care reform in the US demands low cost alternatives • Opiates kill more people than MVAs in US $309B • Positive Clinical Trial data treating low back pain $243B $188B • $560B market with significant barriers for competitors • FD
Slide 15: Compelling Clinical Data in Chronic Low Back Pain
45% Reduction in Pain Compelling Clinical Data in For personal use only Chronic Low Back Pain * Peer reviewed publication in May 2015 BMC Musculo Skeletal Journal, (Assc Prof Peter Kent, Denmark) (P<0.001) • A multi-center, cluster randomized, placebo- controlled trial 73% Increase in Function • Cli
Slide 16: Fundamentally Changing Clinical Practice
Fundamentally Changing Clinical Practice For personal use only • Goal: Be the standard of care in clinical work • dorsaVi well positioned: • Regulatory clearance • Very positive Clinical Trial data • Clear reimbursement plan • Payers want a proven treatment protocol • Payers need to know treatment i
Slide 17: Used across all aspects of patient management
Used across all aspects of patient management Assessment: FDA Cleared For personal use only Advice: Educational & engaging to empower patient Training: Exercise: Movement Stand alone re-education patient driven with live exercises with data feedback live visual biofeedback 17
Slide 18: Fully Functional across 80% of clinical sessions
Fully Functional across 80% of clinical sessions Hamstring Running For personal use only Knee Control Core Control 18
Slide 19: Large Scale Clinical Chains
Large Scale Clinical Chains For personal use only UK distribution deal • 100 physio clinics in UK and Ireland with plans to expand rapidly • Three year deal includes minimum sales targets of 100, 300 and 600 ViMove units • Potential deal valued of AU$9M over the three years (if minimum targets achie
Slide 20: Global penetration > devices in market
Global penetration > 240 devices in market For personal use only 130 devices (Aust) 55 devices (Europe) 55 devices (USA) Aust 24,000 Physios USA UK 284,000 (0.5% Penetration) 48,000 Physios Physical Therapists Immediate target market: > 350,000 Physios (with a greater number of Doctors) Annuity mode
Slide 21: Elite Sports - $160B Market
Elite Sports - $160B Market For personal use only • Sports providing great PR and validation • Drives new cutting edge innovation (clinical and OHS relevant) • A number of commercial injury prevention projects • Unique insights provided to world’s biggest sporting brands • Leverage into consumer wea
Slide 22: Used for injury prevention and assessment at the highest level
Used for injury prevention and assessment at the highest level • Hamstring – AFL, NFL, NBA, EPL • Return to play decisions - AFL, NFL, NBA For personal use only • Knee – AFL, NFL, NBA, EPL • Running – EPL, AFL, NFL, NBA 22
Slide 23: Exciting Tech Development Schedule
Exciting Tech Development Schedule For personal use only dorsaVi through the ‘Continuum of Care’ Dynamic Alignment Long term Early Markers for Post surgery OHS Clinical Sport Prevention Surgery during monitoring Management Surgery acute rehab Waiting List Surgery and support • Multiple options for ‘
Slide 24: Synergy between OHS and Clinical market
Synergy between OHS and Clinical market For personal use only 24
Slide 25: Upcoming Milestones/Newsflow
Upcoming Milestones/Newsflow For personal use only • Long term OHS contracts with major corporates (US, UK & Aust) • Repeat deals with major insurers • Recruit first patient into US low back registry • Publication of Health Economic evaluation from large clinical trial • Multiple US elite sports acr
Slide 26: Appendix
For personal use only Appendix 26
Slide 27: Board and Senior Management
For personal use only Board and Senior Management Chairman Non Executive Director Non Executive Director Non Executive Director Herb Elliott Greg Tweedly Michael Panaccio Ash Attia Director & CEO Andrew Ronchi CFO CIO CMO Head of Sales and Head of Sales and Head of Sales and Damian Connellan Meagan